About this Event
*Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration.
Bear Creek Capital Presents
Kaida BioPharma Inc. (PRIVATE)
Friday, June 28, 2024
Company Presentation and Lunch
Ruth's Chris Steak House
651 Okeechobee Boulevard
West Palm Beach, FL 33401
Promptly at 12:00 PM
Join Kaida BioPharma, Inc. in this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. Kaida is a private startup built by recognized Biotech professionals.
We hope you can join our presentation
Kaida BioPharma Inc. Overview
Dedicated to advancing ovarian cancer treatment through innovative drug development of specific, targeted small molecules, Kaida BioPharma (KBP) was created from the early foundations and clinical evidence of the discovery and research surrounding G129R, a growth hormone antagonist that binds to the prolactin receptor thus inducing self-induced cell death (autophagy). In gynecologic cancers Prolactin is overexpressed in approximately 80% of the patient population thus making it a primary indicator for cancer tumor development.
The Company successfully validated this and focused its goal on increasing the half-life and delivery in the reformulation of the original molecule which led to the filing of the patent for KBX114 a New Molecular Entity and the partnering with Likarda on delivery. With key research center partners at MD Anderson Cancer Center and Thomas Jefferson Hospital, Kaida BioPharma is taking a new approach to human growth hormone cancer treatment and has actively pursued the open IND filing for G129R in Ovarian Cancer with the FDA. The Company expects to be in the clinic in Q1 2025.
Kaida BioPharma's ultimate goal is to seek FDA approval as a combination therapy and get recognized in all 5 treatment arms for Ovarian and Uterine cancer and be the therapeutic of choice for maintenance therapy.
No matter the market, Cancer is still a major concern that continues to draw investment for a cure. Valuations for Phase 1 Ovarian Cancer Companies range from 280M -1.8B
Presentation Format:
12:00 p.m. to 1:30 p.m. – Presentation and Lunch
Contact:
Raymond Oliver
CEO, Bear Creek Capital
321-439-2120
Event Venue & Nearby Stays
Ruth's Chris Steak House, 651 Okeechobee Boulevard, West Palm Beach, United States
USD 0.00
